Overactive Bladder - Pipeline Review, H1 2018

Publication ID: GMD0418071
Publication Date: April 30, 2018
Pages: 110
Publisher: Global Markets Direct
Region: Global

$2,000.00

Publication License Type *
- Single User License (PDF), $2,000.00
- Site License (PDF), $4,000.00
- Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab “Report License Types” below.

Add to cart

Description:
Overactive Bladder - Pipeline Review, H1 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2018, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that’s difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 5, 6, 6, 2, 10 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Contents:**

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Overactive Bladder - Overview
Overactive Bladder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Overactive Bladder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Overactive Bladder - Companies Involved in Therapeutics Development
Allergan Plc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
Dompe Farmaceutici SpA
Dong-A ST Co Ltd
FemmePharma Global Healthcare Inc
Hanmi Pharmaceuticals Co Ltd
Hydra Biosciences Inc
Ion Channel Innovations LLC
Ipsen SA
Juniper Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Medy-Tox Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Mylan NV
Pfizer Inc
Recordati SpA
Taiho Pharmaceutical Co Ltd
Taris Biomedical LLC
TheraVida Inc
Toray Industries Inc
XuanZhu Pharma Co Ltd
Overactive Bladder - Drug Profiles
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-687 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize PACAP Receptor for Anxiety, Overactive Bladder and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0438 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize PTGER1 for Overactive Bladder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solifenacin succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solifenacin succinate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAC-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vibegron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones

Featured News & Press Releases
Mar 28, 2018: Urovant Sciences Initiates Phase 3 Clinical Program for Vibegron in Patients with Overactive Bladder
Mar 19, 2018: Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB)
Mar 09, 2018: Astellas Received Approval for Solifenacin Oral Suspension for Pediatric Patients in Europe
Feb 28, 2018: Urovant Sciences Announces Upcoming Presentations of Data from Phase 2b Trial of Vibegron in Patients with Overactive Bladder
Jan 17, 2018: Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA
Nov 06, 2017: UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel in Combination with BOTOX for the Treatment of Overactive Bladder
Sep 12, 2017: U.S. FDA Accepts for Review Astellas’ Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
Jul 19, 2017: Investigational New Drug Application for RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan
Jun 30, 2017: Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
Oct 27, 2016: Velicept Therapeutics Names Clarence Young, M.D., Chief Medical Officer
Oct 07, 2016: Astellas Filed Lawsuit against Patent Infringement of Myrbetriq in the United States
Oct 05, 2016: Velicept Therapeutics Announces FDA Acceptance of IND Application of Novel, Once-Daily Formulation of Solabegron for the Treatment of Overactive Bladder
Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver
May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego
Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Table 1: Number of Products under Development for Overactive Bladder, H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 4: Number of Products under Development by Universities/Institutes, H1 2018
Table 5: Products under Development by Companies, H1 2018
Table 6: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 7: Products under Development by Universities/Institutes, H1 2018
Table 8: Number of Products by Stage and Target, H1 2018
Table 9: Number of Products by Stage and Mechanism of Action, H1 2018
Table 10: Number of Products by Stage and Route of Administration, H1 2018
Table 11: Number of Products by Stage and Molecule Type, H1 2018
Table 12: Overactive Bladder - Pipeline by Allergan Plc, H1 2018
Table 13: Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp, H1 2018
Table 14: Overactive Bladder - Pipeline by Astellas Pharma Inc, H1 2018
Table 15: Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H1 2018
Table 16: Overactive Bladder - Pipeline by Dong-A ST Co Ltd, H1 2018
Table 17: Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H1 2018
Table 18: Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Table 19: Overactive Bladder - Pipeline by Hydra Biosciences Inc, H1 2018
Table 20: Overactive Bladder - Pipeline by Ion Channel Innovations LLC, H1 2018
Table 21: Overactive Bladder - Pipeline by Ipsen SA, H1 2018
Table 22: Overactive Bladder - Pipeline by Juniper Pharmaceuticals Inc, H1 2018
Table 23: Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
Table 24: Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Table 25: Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, H1 2018
Table 26: Overactive Bladder - Pipeline by Medy-Tox Inc, H1 2018
Table 27: Overactive Bladder - Pipeline by Merck & Co Inc, H1 2018
Table 28: Overactive Bladder - Pipeline by Mezzion Pharma Co Ltd, H1 2018
Table 29: Overactive Bladder - Pipeline by Mylan NV, H1 2018
Table 30: Overactive Bladder - Pipeline by Pfizer Inc, H1 2018
Table 31: Overactive Bladder - Pipeline by Recordati SpA, H1 2018
Table 32: Overactive Bladder - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018
Table 33: Overactive Bladder - Pipeline by Taris Biomedical LLC, H1 2018
Table 34: Overactive Bladder - Pipeline by TheraVida Inc, H1 2018
Table 35: Overactive Bladder - Pipeline by Toray Industries Inc, H1 2018
Table 36: Overactive Bladder - Pipeline by XuanZhu Pharma Co Ltd, H1 2018
Table 37: Overactive Bladder - Dormant Projects, H1 2018
Table 38: Overactive Bladder - Dormant Projects, H1 2018 (Contd..1), H1 2018
Table 39: Overactive Bladder - Dormant Projects, H1 2018 (Contd..2), H1 2018
Table 40: Overactive Bladder - Dormant Projects, H1 2018 (Contd..3), H1 2018
Table 41: Overactive Bladder - Discontinued Products, H1 2018

List of Figures
List of Figures
Figure 1: Number of Products under Development for Overactive Bladder, H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products by Top 10 Targets, H1 2018
Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018
Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Figure 7: Number of Products by Routes of Administration, H1 2018
Figure 8: Number of Products by Stage and Routes of Administration, H1 2018
Figure 9: Number of Products by Molecule Types, H1 2018
Figure 10: Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned:
Allergan Plc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
Dompe Farmaceutici SpA
Dong-A ST Co Ltd
FemmePharma Global Healthcare Inc  
Hanmi Pharmaceuticals Co Ltd  
Hydra Biosciences Inc  
Ion Channel Innovations LLC  
Ipsen SA  
Juniper Pharmaceuticals Inc  
Kissei Pharmaceutical Co Ltd  
Kyorin Pharmaceutical Co Ltd  
Lipella Pharmaceuticals Inc  
Medy-Tox Inc  
Merck & Co Inc  
Mezzion Pharma Co Ltd  
Mylan NV  
Pfizer Inc  
Recordati SpA  
Taiho Pharmaceutical Co Ltd  
Taris Biomedical LLC  
TheraVida Inc  
Toray Industries Inc  
XuanZhu Pharma Co Ltd  

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
• These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
• These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
• Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
• Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

• This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
• Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
• These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.
RECENT POSTS

What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10

Source URL: https://www.drugpipeline.net/global-markets-direct/overactive-bladder-pipeline-review-h1-2018

Links
[1] https://www.drugpipeline.net/region/global